Orion Oyj (FRA:OFK)

Market Cap	9.74B +32.9%
Revenue (ttm)	1.89B +22.5%
Net Income	500.30M +51.7%
EPS	3.56 +51.5%
Shares Out	n/a
PE Ratio	19.46
Forward PE	18.91
Dividend	1.72 (2.49%)
Ex-Dividend Date	Mar 25, 2026

Volume	n/a
Average Volume	14
Open	69.60
Previous Close	69.45
Day's Range	69.25 - 69.60
52-Week Range	47.60 - 74.85
Beta	n/a
RSI	49.63
Earnings Date	Feb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,029
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OFK

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.